Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ecopipam in Adults With Childhood Onset Fluency Disorder
NCT02909088Phase 3Unknown
- Start
- Sep 2016
- Primary completion
- Aug 2017
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ecopipam in childhood-onset fluency disorder (COFD). Primary endpoint: Stuttering Severity Instrument Version IV at 8 weeks. Status: unknown.
02
Drugs
ecopipam
03
Conditions
childhood-onset fluency disorder (COFD)
Beyond the preview
Go deeper on NCT02909088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02909088.